Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Postma

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Plos One|April 4, 2014
Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modellingElisabetta De Cao, Alessia Melegaro, Rogier Klok, et al.
Frontiers in Pharmacology|June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesHans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Health Economics|September 29, 2006
Discounting in economic evaluations: stepping forward towards optimal decision rulesHugh Gravelle, Werner Brouwer, Louis Niessen, et al.
Pharmacoeconomics|March 29, 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic AreasBart Heeg, Dawn Lee, Jane Adam, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Extrapolating Survival Data Using Historical Trial-Based a Priori DistributionsFanni Soikkeli, Mahmoud Hashim, Mario Ouwens, et al.
Vaccine|February 16, 2025
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputsDarvin S Smith, Maarten Postma, David Fisman, et al.
Vaccine|November 26, 2008
Evolution of the health economics of cervical cancer vaccinationNicole Ferko, Maarten Postma, Steve Gallivan, et al.
Advances in Therapy|October 22, 2014
Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?Baudouin Standaert, Olivier Ethgen, Rachel Emerson, et al.
Diseases (Basel, Switzerland)|December 27, 2024
Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North AmericaDavid Fisman, Maarten Postma, Myron J Levin, et al.
Pharmacoeconomics|July 14, 2012
The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysisMark P Connolly, Oleksandr Topachevskyi, Baudouin Standaert, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Plos One|April 4, 2014
Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modellingElisabetta De Cao, Alessia Melegaro, Rogier Klok, et al.
Frontiers in Pharmacology|June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesHans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Health Economics|September 29, 2006
Discounting in economic evaluations: stepping forward towards optimal decision rulesHugh Gravelle, Werner Brouwer, Louis Niessen, et al.
Pharmacoeconomics|March 29, 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic AreasBart Heeg, Dawn Lee, Jane Adam, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Extrapolating Survival Data Using Historical Trial-Based a Priori DistributionsFanni Soikkeli, Mahmoud Hashim, Mario Ouwens, et al.
Vaccine|February 16, 2025
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputsDarvin S Smith, Maarten Postma, David Fisman, et al.
Vaccine|November 26, 2008
Evolution of the health economics of cervical cancer vaccinationNicole Ferko, Maarten Postma, Steve Gallivan, et al.
Advances in Therapy|October 22, 2014
Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?Baudouin Standaert, Olivier Ethgen, Rachel Emerson, et al.
Diseases (Basel, Switzerland)|December 27, 2024
Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North AmericaDavid Fisman, Maarten Postma, Myron J Levin, et al.
Pharmacoeconomics|July 14, 2012
The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysisMark P Connolly, Oleksandr Topachevskyi, Baudouin Standaert, et al.
Pageof 10